Locations:
Search IconSearch

GI

22-DDI-3242262 – Neuroendocrine Tumor-Kim-3-hero
December 15, 2022/Cancer

Neuroendocrine Tumors: Today’s GIs Likely Will Encounter Them

Cleveland Clinic program to streamline clinical care and research

19-DDI-6059-IBD-CQD
June 4, 2021/Digestive/GI

Biosimilar Safety and Efficacy Comparable to Biologic Treatment in IBD Patients

Infliximab-abda offers similar benefits at lower costs

21-DDI-2066394-CCJM-Curbside-GI-Manifestations
March 1, 2021/COVID-19

Gastrointestinal Manifestations of COVID-19

Prevalence, characteristics and disease course

20-DDI-1983916-ACG-Decreasing-Colectomy-UC-Biologic-Medications
October 26, 2020/Digestive/GI

20 Years of Colectomy and Biologics for Ulcerative Colitis

How rates of colectomy and biologics use have changed over time

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

16-DDI-2083-Lynch-FAP-CQD-650×450
September 22, 2016/Cancer

Managing Lynch and FAP: A Balance Between Cancer Prevention and Quality of Life

Action items for managing these complex patients

16-DDI-1472-HIPEC-CQD-650×450
August 23, 2016/Cancer

HIPEC for GI Cancers Lowers Morbidity and Mortality

Yet insurance restricts its utility

16-DDI-052-Biosimilars-CQD+650×450
February 1, 2016/Digestive/GI

Biosimilars Could Change How Physicians Treat Inflammatory Bowel Disease

Lower cost option increases access to therapies

15-CCR-2478-Hepatitis-C-650×450
December 16, 2015/Digestive/GI

Hepatitis C: New Direct-Acting Antivirals Expand Primary Care Physicians’ Role

Newer noninvasive tests allow many patients to avoid liver biopsy

BackPage 1 of 2Next

Advertisement

Ad